|
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)
Item Type: | Article |
---|
Title: | Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883) |
---|
Creators Name: | Hauke, J. and Harter, P. and Ernst, C. and Burges, A. and Schmidt, S. and Reuss, A. and Borde, J. and De Gregorio, N. and Dietrich, D. and El-Balat, A. and Kayali, M. and Gevensleben, H. and Hilpert, F. and Altmüller, J. and Heimbach, A. and Meier, W. and Schoemig-Markiefka, B. and Thiele, H. and Kimmig, R. and Nürnberg, P. and Kast, K. and Richters, L. and Sehouli, J. and Schmutzler, R.K. and Hahnen, E. |
---|
Abstract: | Variant-specific loss of heterozygosity (LOH) analyses may be useful to classify BRCA1/2 germline variants of unknown significance (VUS). The sensitivity and specificity of this approach, however, remains unknown. We performed comparative next-generation sequencing analyses of the BRCA1/2 genes using blood-derived and tumour-derived DNA of 488 patients with ovarian cancer enrolled in the observational AGO-TR1 trial (NCT02222883). Overall, 94 pathogenic, 90 benign and 24 VUS were identified in the germline. A significantly increased variant fraction (VF) of a germline variant in the tumour indicates loss of the wild-type allele; a decreased VF indicates loss of the variant allele. We demonstrate that significantly increased VFs predict pathogenicity with high sensitivity (0.84, 95% CI 0.77 to 0.91), poor specificity (0.63, 95% CI 0.53 to 0.73) and poor positive predictive value (PPV; 0.71, 95% CI 0.62 to 0.79). Significantly decreased VFs predict benignity with low sensitivity (0.26, 95% CI 0.17 to 0.35), high specificity (1.0, 95% CI 0.96 to 1.00) and PPV (1.0, 95% CI 0.85 to 1.00). Variant classification based on significantly increased VFs results in an unacceptable proportion of false-positive results. A significantly decreased VF in the tumour may be exploited as a reliable predictor for benignity, with no false-negative result observed. When applying the latter approach, VUS identified in four patients can now be considered benign. Trial registration number NCT02222883. |
---|
Keywords: | BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, BRCA1 Genes, Genetic Predisposition to Disease, Germ Cells, Germ-Line Mutation, Loss of Heterozygosity, Ovarian Neoplasms |
---|
Source: | Journal of Medical Genetics |
---|
ISSN: | 0022-2593 |
---|
Publisher: | BMJ Publishing Group |
---|
Volume: | 59 |
---|
Number: | 3 |
---|
Page Range: | 248-252 |
---|
Date: | March 2022 |
---|
Official Publication: | https://doi.org/10.1136/jmedgenet-2020-107353 |
---|
PubMed: | View item in PubMed |
---|
Repository Staff Only: item control page
Downloads per month over past year
|
|
|